MedImmune
Parent AstraZeneca | | |
Website | www.medimmune.com[dead link] |
---|
MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca.[1][2]
MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion.
It produced
FluMist was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market—young children who find injections objectionable. Sales of FluMist fell short of analysts' expectations for the first two years the drug was sold. FluMist was initially sold in a frozen form, which was difficult for doctors to store.[6]
MedImmune conducted successful
History
Molecular Vaccines, Inc. was founded by Wayne T. Hockmeyer, David Mott, and Dr. James Young in 1988.[6] In 1989, Molecular Vaccines, Inc changed its name to MedImmune, Inc.
On April 23, 2007, it was announced MedImmune and AstraZeneca entered into a definitive agreement under which AstraZeneca intended to acquire MedImmune in an all-cash transaction at US$ 58 per share, or about US$ 15.2 billion.[6] On 19 June 2007 AstraZeneca completed the acquisition paying US$ 15.2 billion primarily for its drug development pipeline. Analysts have criticised the take-over, claiming that AstraZeneca paid too much.[7] AstraZeneca chose to merge MedImmune with Cambridge Antibody Technology, which it had acquired in 2006, creating a new biologics division under the MedImmune name. AstraZeneca presented the new MedImmune to investors on 7 December 2007.[8]
In June 2007, the
MedImmune said it was making a significant, rapid response with a vaccine to the
MedImmune received approval from the U.S. FDA for its intranasal novel H1N1 influenza vaccine in September 2009.[10]
Pipeline
MedImmune had over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer. Major phase III trials included:[12]
- durvalumab (anti-PD-L1)
- tremelimumab (anti-CTLA-4)
- moxetumomab pasudotox (anti-CD22)
- benralizumab (anti-IL-5R)
- tralokinumab (anti-IL-13)
- anifrolumab (anti-IFN-aR)
- nirsevimab (anti-RSV)
See also
References and notes
- ^ "12 years on, Astra draws a line under Medimmune". Evaluate.com. 2019-02-14. Retrieved 2019-02-15.
- ^ "AstraZeneca retires Medimmune name amid sales turnaround". BioPharma Dive. Retrieved 2019-02-16.
- ^ Pollack, Andrew (24 April 2007). "AstraZeneca Buys MedImmune for $15.6 Billion". Retrieved 2 June 2019 – via NYTimes.com.
- ^ "About Us | MedImmune". Archived from the original on 2017-08-30. Retrieved 2017-08-23.
- ^ a b Michael S. Rosenwald (June 2, 2009). "MedImmune Wins Key Contract To Develop Swine Flu Vaccine". The Washington Post. Retrieved October 23, 2009.
- ^ a b c
- Medimmune Company Site
- Flumist nasal flu vaccine - Official website
- Bishop, Tricia. "MedImmune loss in '05 quadruples shortfall from '04" Baltimore Sun. 3 February 2006.
- Rosenwald, Michael S. "Sales of MedImmune's Flu Vaccine Drop Sharply" Washington Post. 3 February 2006.
- ^ "AstraZeneca's $15 Billion Buy of MedImmune buy too costly, some say". Money.cnn.com. Retrieved 2 June 2019.
- ^ "Media Centre - AstraZeneca". Astrazeneca.com. Retrieved 2 June 2019.
- ^ MedImmune Press release MedImmune and National Institutes of Health Begin Clinical Testing of a Live, Attenuated Intranasal Vaccine Against an H5N1 Avian Influenza Virus published June 15, 2007
- ^ a b "MedImmune Influenza A (H1N1) Information". Archived from the original on September 24, 2009. Retrieved October 23, 2009.
- ^ Sinha, Vandana (13 July 2009). "MedImmune gets second H1N1 flu contract".
- ^ "Pipeline - AstraZeneca". Astrazeneca.com. Retrieved 2 June 2019.